Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation

Transplantation

Volumn 78, Issue 6, 2004, Pages 911-918

  Pihusch, Markus ^a,b   Lohse, Peter ^b   Reitberger, Jill ^b   Hiller, Erhard ^b   Andreesen, Reinhard ^a   Kolb, Hans Jochem ^b,c   Holler, Ernst ^a   Pihusch, Rudolf ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Hematopoietic stem cell transplantation; Hemostatic complication; Thrombophilic gene mutation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMSACRINE; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE; ETOPOSIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASIA; ARTICLE; CATHETER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRON; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOPHILIA; VEIN OCCLUSION;

ADOLESCENT; ADULT; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; STEM CELL TRANSPLANTATION; THROMBOEMBOLISM; TRANSPLANTATION, HOMOLOGOUS;

EID: 4644337719     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000136988.38919.FB     Document Type: Article

References (29)

1. Pihusch R, Salat C, Schmidt E, et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74(9): 1303.
2. Pihusch R, Wegner H, Salat C, et al. Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30(6): 381.
3. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369(6475): 64.
4. Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90(5): 1747.
5. Arruda VR, von-Zuben PM, Chiaparini LC, et al. The mutation Ala677->Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77(5): 818.
6. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95(5): 1517.
7. Mamotte CDS, Bockxmeer FW, Taylor RR. Pla1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol 1998; 82(1): 13.
8. Humphries SE, Ye S, Talmud P, et al. European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol 1995; 15(1): 96.
9. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98(1): 231.
10. Matsuo K, Suzuki R, Morishima Y, et al. Attribution of posttransplantation toxicity to methotrexate regarding genotype of methylenetetrahydrofolate reductase gene (MTHFR) polymorphism needs further clarification. Blood 2001; 98(7): 2283.
11. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44(6): 778.
12. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989; 73(7): 2018.
13. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev 1985; 88: 215.
14. Riordan M, Weiden PL. Factor V Leiden mutation does not account for central venous catheter-related thrombosis. Am J Hematol 1998; 58(2): 150.
15. Sartori MT, Wiman B, Vettore S, et al. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998; 80(6): 956.
16. Hill SL, Berry RE. Subclavian vein thrombosis: a continuing challenge. Surgery 1990; 108(1): 1.
17. Eissner G, Multhoff G, Gerbitz A, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002; 100(1): 334.
18. Dumler JS, Bechorner WE, Farmer ER, et al. Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol 1989; 135(6): 1097.
19. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75(4): 1011.
20. Lindner H, Holler E, Ertl B, et al. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. Blood 1997; 89(6): 1931.
21. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163(3): 740.
22. Medcalf RL, Kruithof EK, Schleuning WD. Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J Exp Med 1988; 168(2): 751.
23. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92(10): 3599.
24. Shulman HM, Fisher LB, Schoch HG, et al. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19(5): 1171.
25. Rozman C, Carreras E, Qian C, et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996; 17: 75.
26. Salat C, Holler E, Kolb HJ, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89(6): 2184.
27. Iacoviello L, Burzotta F, Di Castelnuovo A, et al. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998; 80(6): 1029.
28. Toffoli G, Russo A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103(3): 294.
29. Fischereder M, Schneeberger H, Lohse P, et al. Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. Am J Kidney Dis 2001; 38(5): 1061.